Products - Ovarian cancer | Topic | NICE

Showing 7 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) (TA560)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
20 February 2019
Olaparib for maintenance treatment of ovarian, fallopian tube or peritoneal cancer that has a BRCA germline mutation after response to first-line platinum-based chemotherapy [ID1124]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
31 July 2019
Rucaparib for maintenance treatment of recurrent platinum-sensitive epithelial ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy [ID1485]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
2 October 2019
Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (including a review of technology appraisal no. 381) [ID1296]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC